Kanabo Group Plc (LSE: KNB)
Health Care · Pharmaceuticals · GB
£—
— today · — 1Y
Kanabo Group Plc (LSE: KNB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.86M and employs 20 people.
trading between 0.00 and 0.00.
Tweenvest scores Kanabo Group Plc across four factors: quality 28/100, value 38/100. Its strongest factor is value.
KNB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.86M
- Revenue (TTM)
- $1.44M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 2.31
- 52-week high
- £0.00
- 52-week low
- £0.00
- Avg volume (3M)
- —
- Shares outstanding
- 632.43M
- Employees
- 20
- Next earnings
- —
About Kanabo Group Plc
Kanabo Group Plc specializes in the creation and distribution of cannabis-derived offerings tailored for medical patients. The company also provides cannabidiol (CBD) products, specifically those without tetrahydrocannabinol (THC), for general consumers. All its merchandise is marketed under the Kanabo brand. Founded in 2016, this London, United Kingdom-based firm operates as a subsidiary of Altshuler Shaham Trusts Ltd.
- ISIN
- GB00BYQCS703
- Founded
- 2016
- Listed since
- May 17, 2017
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.03 | +0.01% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $270.99 | -0.75% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.72 | +0.04% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.00 | +0.16% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.66 | +0.46% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.98 | +0.04% |
Figures last refreshed Aug 18, 2026.